ARTICLE | Product Development
Seeking CD3
How Xencor's bispecifics fill gap in Novartis' immuno-oncology portfolio
July 11, 2016 7:00 AM UTC
Novartis AG has picked Xencor Inc. to fill a gap in the pharma's immuno-oncology armamentarium, adding a new modality to its portfolio with a different range of activity than its current arsenal.
For Xencor, the June 28 deal reflects the biotech's ability to progressively keep more upside, thanks to a better capital position and maturation of its bispecific platform...